Epinephrine.

Tyrosine is hydroxylated to DOPA and then converted stepwise through dopamine and norepinephrine to epinephrine. It is the amino acid input to the whole catecholamine chain.

Phenylalanine hydroxylase converts phenylalanine into tyrosine, one step above the catecholamine route. It therefore feeds the same synthesis chain a level earlier.

Dopamine beta-hydroxylase, which converts dopamine into norepinephrine, uses ascorbate as its electron donor and is concentrated in catecholamine storage vesicles. Ascorbate supply is a direct input to that conversion step.

Dopamine beta-hydroxylase is a copper-containing enzyme, so copper status sets the capacity of the step that makes norepinephrine. Epinephrine is one methylation further along the same chain.

Tyrosine hydroxylase, the rate-setting enzyme of catecholamine synthesis, is an iron-dependent hydroxylase. Iron status governs how fast tyrosine enters the pathway at all.

Aromatic amino acid decarboxylase converts DOPA into dopamine using pyridoxal-5-phosphate as its cofactor. Active B6 supply is required for that step in the catecholamine chain.

Phenylethanolamine N-methyltransferase adds a methyl group to norepinephrine to make epinephrine, and S-adenosylmethionine is the donor. It is also the donor for catechol-O-methyltransferase, the enzyme that inactivates catecholamines.

Methylfolate regenerates methionine from homocysteine and so replenishes S-adenosylmethionine. That donor pool is what both the final methylation to epinephrine and its O-methyl breakdown draw on.

Caffeine blocks adenosine receptors and raises circulating catecholamines, so its cardiovascular and metabolic effects run in the same direction as adrenergic signalling. The two add on heart rate and mobilisation of fuel.

Catechins inhibit catechol-O-methyltransferase, the enzyme that methylates and inactivates catecholamines. Slowing that clearance prolongs adrenergic signalling from a given amount of epinephrine.

Octopamine is a trace amine that acts at adrenergic receptors in the same direction as epinephrine. Combined use adds at the receptor rather than through separate routes.

Hordenine inhibits monoamine oxidase B and releases stored catecholamines, which extends adrenergic signalling. Stacking it with adrenergic agents raises the combined sympathetic load.

Octodrine is an aliphatic amine that raises norepinephrine release and acts at adrenergic receptors. Its cardiovascular effects add to those of epinephrine rather than balancing them.

Magnesium dampens catecholamine release from nerve endings and from the adrenal medulla, and it blunts the calcium entry that adrenergic signalling drives. Its effect on vascular tone and heart rate runs opposite to adrenergic activation.

Theanine moderates the rise in blood pressure and subjective arousal that accompanies sympathetic stimulation. It is added to stimulant formulas for that smoothing effect rather than for any additive drive.

Taurine stabilises calcium handling in cardiac muscle, which is the same intracellular step adrenergic signalling amplifies. It is used alongside stimulants to moderate that amplification.

The final step of adrenaline synthesis is the methylation of noradrenaline by phenylethanolamine N-methyltransferase, which consumes S-adenosylmethionine and yields S-adenosylhomocysteine. Betaine regenerates methionine from homocysteine through betaine-homocysteine methyltransferase, feeding the SAM pool that step draws on. This is settled biochemistry rather than a supplementation result.

Methionine is the direct precursor of S-adenosylmethionine, the methyl donor used by phenylethanolamine N-methyltransferase to convert noradrenaline to adrenaline and by catechol-O-methyltransferase to inactivate it. Both the synthesis and the clearance of the molecule run on the same methyl pool. That the same pool serves both directions is worth stating plainly.

Monoamine oxidase, one of the two enzymes that degrade adrenaline, is a flavin adenine dinucleotide enzyme, and FAD is made from riboflavin. Riboflavin also supports the flavin-dependent regeneration of tetrahydrobiopterin, the cofactor tyrosine hydroxylase needs at the first step of catecholamine synthesis. The nutrient sits on both ends of the pathway.

Beta-2 adrenergic stimulation drives potassium from the extracellular space into skeletal muscle by activating the sodium-potassium ATPase. This lowers circulating potassium acutely and is the standard textbook explanation for the fall seen during an adrenergic surge. It is a distribution shift rather than a change in total body potassium.

Beta-adrenergic receptors raise cyclic AMP, protein kinase A then phosphorylates calcium-handling proteins, and intracellular calcium cycling changes as a result. Calcium is the downstream messenger for a large part of what the receptor does. This is signalling biochemistry and not a statement about a calcium supplement.

Quercetin is a catechol-containing flavonoid and an established inhibitor of catechol-O-methyltransferase in cell-free systems, competing with catecholamines for the same enzyme and the same methyl donor. Slowing that route would extend the presence of circulating catecholamines. Whether ordinary oral doses do this in people has not been established.

Rhodiola's salidroside and rosavin fraction has been reported to affect monoamine turnover in animal models, including the adrenal catecholamines. The evidence is preclinical and the direction of effect is not consistent across models. It is a mechanistic lead rather than a human finding.

Ashwagandha root extracts have been studied against cortisol and self-reported stress in adults, endpoints that sit on the same hypothalamic-pituitary-adrenal axis that governs adrenal medullary output. Cortisol is a marker on that axis, not a measure of circulating adrenaline. The link between the two is anatomical and regulatory rather than demonstrated for this pairing.

Adrenergic input from the sympathetic nervous system is what drives pineal melatonin synthesis at night, acting through beta-1 receptors on pinealocytes to raise cyclic AMP and induce arylalkylamine N-acetyltransferase. The relationship is regulatory and directional: noradrenergic signalling turns melatonin production on. Beta blockade is the classic demonstration of the link.